semaglutide osa is changing the conversation around metabolic health. While most people know it for diabetes and weight management, emerging research is exploring its potential benefits in conditions like: • Fatty Liver (NAFLD/NASH) Tirzepatide and Semaglutide: Impact on

These data suggest early signals of semaglutide responsiveness and relationships to epigenetic age biomarkers

Current published research most commonly discusses gastrointestinal events such as nausea, diarrhoea, vomiting and constipation

Learn about the biological processes these medications target in your body and understand why they represent such a significant breakthrough compared to traditional diet approaches

Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%

Extreme fluctuations in hormonal levels are associated with longer periods of amenorrhea (i.e., absence of menstrual periods), at least 60 days

These timing and dietary adjustments address the root cause of sleep disruption rather than masking it with sleep aids